55.7 F
San Diego
Tuesday, Mar 19, 2024
-Advertisement-

Elcelyx Therapeutics Raises $40 Million in Series E Round

San Diego-based Elcelyx Therapeutics announced Oct. 1 that it has secured $40 million in a Series E financing.

The announcement comes after the company received official guidance from the FDA for late-stage trials of its oral drug candidate, a delayed-release formulation of metformin. The drug is under development to fill the unmet needs of the 40 percent of type 2 diabetes patients who cannot currently use metformin due to contraindications or poor tolerability.

The proceeds of the round will fund a large Phase 2b, dose-ranging clinical trial, according to a recent news release.

The financing was led by Hong Kong-based global private equity firm Sailing Capital and Clough Capital Partners L.P., a Boston-based global investment management firm. Elcelyx’s existing investors Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, Technology Partners, and GSM Fund LLC also participated in the round.

Read more about Elcelyx in the October 12 edition of the San Diego Business Journal.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-